phenylbutazone
Trade name: butazolidin
Approved
Jun 1, 1952
Phenylbutazone is an anti-inflammatory drug, which binds to and inactivates cyclooxygenases and prostacyclin synthase through peroxide (H2O2) mediated deactivation. The reduced production of prostaglandin leads to reduced inflammation of the surrounding tissues. Phenylbutazone was marked under the brand name butazolidin for the treatment rheumatoid arthritis and gout, but then this usage was discontinued. In addition, phenylbutazone is used in UK for the treatment of ankylosing spondylitis, but only in those cases, when other therapies are unsuitable. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 8 marketing orgs
Timeline
1970s
- May 16, 1977
Novartis — NDA Secondary Org
- Oct 29, 1979
Watson Pharmaceuticals — Marketing Organization
1980s
- Jan 10, 1980
Fosun — Marketing Organization
- Oct 13, 1981
Sanofi-Aventis — Marketing Organization
- Jun 16, 1982
Chartwell Pharmaceuticals — Marketing Organization
- Jun 24, 1983
Ivax — Marketing Organization
- Dec 4, 1985
Sun Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Approval history
- approvedJun 1, 1952
Chemistry & pharmacology
SMILES
CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3- Mol. weight
- 308.3743 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaPhenylbutazone ↗
- NCATSGN5P7K3T8S ↗
- ChEMBLCHEMBL114503 ↗
- ChEMBLCHEMBL101 ↗
Also known as
- 3,5-dioxo-1,2-diphenyl-4-n-butylpyrazolidine
- 3,5-dioxo-1,2-diphenyl-4-n-butylpyrazolidine
- 4-butyl-1,2-diphenyl-pyrazolidine-3,5-dione
- 4-butyl-1,2-diphenyl-pyrazolidine-3,5-dione
- 4-n-butyl-1,2-diphenyl-3,5-pyrazolidinedione
- 4-n-butyl-1,2-diphenyl-3,5-pyrazolidinedione
- antadol
- antadol
- azolid
- azolid
- butacote
- butacote
- butaject
- butazolidin
- butazolidin
- butazolidin
- diphenylbutazone
- diphenylbutazone
- elmedal
- elmedal
- equiphar
- fenilbutazona
- fenilbutazona
- phenbutazone
- phenbutazone
- phenylbutazon
- phenylbutazon
- phenylbutazon
- phenylbutazone
- phenylbutazone
- phenylbutazone
- phenylbutazone
- phenylbutazone
- phenylbutazone
- phenylbutazone
- phenylbutazone
- phenylbutazone
- phenylbutazonum
- phenylbutazonum
- pro-bute
Organizations
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Chartwell Pharmaceuticals | For profit | MKTG | Jun 16, 1982 |
| Fosun | For profit | MKTG | Jan 10, 1980 |
| Ivax | For profit | MKTG | Jun 24, 1983 |
| Novartis | For profit | NDA2 | May 16, 1977 |
| Sandoz | For profit | NDA | Jun 1, 1952 |
| Sanofi-Aventis | For profit | MKTG | Oct 13, 1981 |
| Sun Pharmaceuticals | For profit | MKTG | Dec 4, 1985 |
| Watson Pharmaceuticals | For profit | MKTG | Oct 29, 1979 |